Showing 6891-6900 of 8845 results for "".
- Dr. Siegel Discusses Sedation Without Drugshttps://practicaldermatology.com/news/Dr-Siegel-Discusses-Sedation-Without-Drugs/2471217/A significant portion of today’s patient population is interested in all-natural alternatives to drugs when possible, and sedation is an area where some useful options exist, according to Daniel M. Siegel, MD. “Sedation without drugs [is important] if you have new-age patients or, I guess,
- Weight-Loss Drugs Highlighted as 'Easy' Option to Improve PsO Therapieshttps://practicaldermatology.com/news/Weight-Loss-Drugs-Highlighted-Easy-Option-Improve-PsO-Therapies/2471215/Any dermatologist not prescribing weight-loss drugs for psoriasis patients who are obese likely will be soon, according to Mark Lebwohl, MD. Dr. Lebwohl, speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, highlighted data indicating an association between como
- 2% Medicare Payment Increase Could Be Imminenthttps://practicaldermatology.com/news/2-Medicare-Payment-Increase-Could-Be-Imminent/2471172/A 2% payment increase for physicians from Medicare appears close after American Academy of Dermatology (AAD) president Seemal Desai, MD, FAAD, attended a congressional session on February 11. “This bill has so much momentum that we are finally on the cusp,” Dr. Desai said during an AAD upd
- POETYK-PSO LTE: No New Safety Signals for Deucravacitinib at Five Yearshttps://practicaldermatology.com/news/poetyk-lte-no-new-safety-signals-for-deucravacitinib-at-five-years/2471170/Sotyktu (deucravacitinib) showed sustained efficacy and an acceptable safety profile over a period of 5 years in adults with moderate-to-severe plaque psoriasis, according to an announcement by Bristol Myers Squibb. Based on rec
- Guselkumab Effective in Psoriasis Regardless of Prior Treatment History: Studyhttps://practicaldermatology.com/news/guselkumab-effective-regardless-of-prior-treatment-history-study/2471126/Guselkumab was effective at managing moderate-to-severe psoriasis over five years, regardless of baseline disease severity or treatment history, according to a post hoc analysis of the VOYAGE 1 and 2 trials. The study looked
- Surgical Excision Outperforms Curettage Plus Imiquimod for nBCChttps://practicaldermatology.com/news/surgical-excision-outperforms-curettage-plus-imiquimod-for-nbcc/2471123/Surgical excision (SE) is significantly more effective than superficial curettage (SC) followed by imiquimod cream, 5%, in maintaining tumor-free survival for nodular basal cell carcinoma (nBCC) after five years, according to a new analysis in JAMA Dermatology.
- Hidradenitis Suppurativa Genetics Linked to Cardiometabolic Riskhttps://practicaldermatology.com/news/hidradenitis-suppurativa-genetics-linked-to-cardiometabolic-risk/2471117/A high polygenic risk score (PRS) for hidradenitis suppurativa (HS) is linked to an increased risk of coronary artery disease (CAD) and diabetes, according to a new analysis of UK Biobank data. Study researchers included 391,481 individuals of European ancestry with data in UK Biobank in t
- Skin Cancer Champions Hosts Event to Brainstorm for Growth, Sustainabilityhttps://practicaldermatology.com/news/Skin-Cancer-Champions-Hosts-Event-Brainstorm-Growth-Sustainability/2471116/The Skin Care Champions nonprofit hosted an innovation tournament at Brigham and Women’s Hospital on February 3, bringing together clinicians, patients, caregivers, industry, and more to brainstorm ideas for the organization to achieve growth and sustainability in the future. Emily S. Ruiz
- Galderma Renews Sensitive Skin Care Research Fund at GWhttps://practicaldermatology.com/news/galderma-renews-sensitive-skin-care-research-fund-at-gw/2471114/Galderma extended its partnership with the Department of Dermatology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS) by renewing the Sensitive Skin Care Research Acceleration Fund to support efforts to redefine the understanding and management of this
- Pacific Northwest Practice Hiringhttps://practicaldermatology.com/news/Pacific-Northwest-Practice-Hiring/2471098/Clear Choice Dermatology announced it is seeking a board-certified dermatologist to work in its locations in Portland, Oregon, or Salem, Oregon. Clear Choice has 11 locations throughout Oregon and Washington. Owner and Chief Medical Officer Collin Blattner, DO, FAAD, is a member of Pra